Johnson & Johnson's ICOTYDE® Shows Promising Two-Year Results in Psoriasis Treatment #USA #Johnson_&_Johnson #Spring_House #Psoriasis #ICOTYDE

Johnson & Johnson's ICOTYDE® Shows Promising Two-Year Results in Psoriasis Treatment #USA #Johnson_&_Johnson #Spring_House #Psoriasis #ICOTYDE
Johnson & Johnson’s ICOTYDE®: Breakthrough Data for Plaque Psoriasis Treatment Demonstrates Long-Term Efficacy #USA #Johnson_&_Johnson #Spring_House #Plaque_Psoriasis #ICOTYDE
Johnson & Johnson Unveils Promising Long-Term Results for IMAAVY® in Generalized Myasthenia Gravis Patients #USA #Johnson_&_Johnson #Spring_House #Myasthenia_Gravis #IMAAVY
TREMFYA® Breakthrough: First IL-23 Inhibitor to Alleviate Spinal Pain in Psoriatic Arthritis #USA #Spring_House #TREMFYA #guselkumab #Psoriatic_Arthritis